

This IssueViews **42,953** | Citations **1,118** | Altmetric **58**

PDF



Full Text



Share



Cite



Permissions

Review

February 16, 2021

Diagnosis and Treatment of Metastatic Colorectal Cancer

A Review

Leah H. Biller, MD^{1,2}; Deborah Schrag, MD, MPH^{1,2,3,4}[» Author Affiliations](#)

JAMA. 2021;325(7):669-685. doi:10.1001/jama.2021.0106



Related Articles

Abstract

Importance Colorectal cancer (CRC) is the third most common cause of cancer mortality worldwide with more than 1.85 million cases and 850 000 deaths annually. Of new colorectal cancer diagnoses, 20% of patients have metastatic disease at presentation and another 25% who present with localized disease will later develop metastases.

Observations Colorectal cancer is the third most common cause of cancer mortality for men and women in the United States, with 53 200 deaths projected in 2020. Among people diagnosed with metastatic colorectal cancer, approximately 70% to 75% of patients survive beyond 1 year, 30% to 35% beyond 3 years, and fewer than 20% beyond 5 years from diagnosis. The primary treatment for unresectable metastatic CRC is systemic therapy (cytotoxic chemotherapy, biologic therapy such as antibodies to cellular growth factors, immunotherapy, and their combinations.) Clinical trials completed in the past 5 years have demonstrated that tailoring treatment to the molecular and pathologic features of the tumor improves overall survival. Genomic profiling to detect somatic variants is important because it identifies the treatments that may be effective. For the 50% of patients with metastatic CRC with *KRAS/NRAS/BRAF* wild-type tumors, cetuximab and panitumumab (monoclonal antibodies to the epithelial growth factor receptor [EGFR]), in

combination with chemotherapy, can extend median survival by 2 to 4 months compared with chemotherapy alone. However, for the 35% to 40% of patients with *KRAS* or *NRAS* sequence variations (formerly termed *mutations*), effective targeted therapies are not yet available. For the 5% to 10% with *BRAF V600E* sequence variations, targeted combination therapy with BRAF and EGFR inhibitors extended overall survival to 9.3 months, compared to 5.9 months for those receiving standard chemotherapy. For the 5% with microsatellite instability (the presence of numerous insertions or deletions at repetitive DNA units) or mismatch repair deficiency, immunotherapy may be used in the first or subsequent line and has improved treatment outcomes with a median overall survival of 31.4 months in previously treated patients.

Conclusions and Relevance Advances in molecular profiling of metastatic CRC facilitate the ability to direct treatments to the biologic features of the tumor for specific patient subsets. Although cures remain uncommon, more patients can anticipate extended survival. Genomic profiling allows treatment selection so that more patients derive benefit and fewer are exposed to toxicity from ineffective therapies.


[Full Text](#)

Access through your institution

Advertisement

Read More About

[Oncology](#)[Genetics and Genomics](#)[Targeted and Immune Therapy](#)[Colorectal Cancer](#)[Gastroenterology](#)[Gastrointestinal Cancer](#)[Gastroenterology and Hepatology](#)



Diagnostic Accuracy of an Integrated AI Tool to Estimate Gestational Age From Blind Ultrasound Sweeps

[Read the study](#)

Artificial Intelligence Resource Center

Our websites may be periodically unavailable between 7:00 PM CT September 7, 2024 and 1:00 AM CT September 8, 2024 for regularly scheduled maintenance.

Trending

Research

Panitumumab vs Bevacizumab and Survival in Patients With RAS Wild-type, Left-Sided Colorectal Cancer

April 18, 2023

Research

Effect of Adding Cetuximab vs Bevacizumab to Chemotherapy for KRAS Wild-Type Colorectal Cancer

June 20, 2017

Research

Association of Patient Characteristics and Tumor Genomics With Non-Small Cell Lung Cancer Outcomes

April 9, 2019

Select Your Interests

Advertisement

JOB LISTINGS ON JAMA CAREER CENTER®

Physician - Hematology/Oncology

Springwoods VillageSpring, Texas

Hematologist/Oncologist Is Needed for Locum Tenens Help in Pennsylvania

Johnstown, Pennsylvania

A Facility in Florida Is Looking for a Locum Tenens Radiation Oncologist

Florida

Facility in WV Needs a Locums Medical Oncologist

Huntington, West Virginia

Radiation Oncologist Is Wanted for Locum Tenens Coverage in OH

Ohio

See more at JAMA Career Center

The Genetic basis of cancer [↗](#)

J.E. van Rensburg, Familia, 1998

Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study [↗](#)

Brought to you by Pfizer Medical affairs

A Case of a Transwoman with Colorectal Cancer after Flap Vaginoplasty [↗](#)

Shiho Watanabe, JPRS, 2023

A Case of Crouzon's Syndrome with a True Human Tail [↗](#)

Nobuhiro Ando, JPRS, 2023

Powered by **TREND** **MD**



Trending

**FOLFIRI Plus Durvalumab
With or Without
Tremelimumab in Advanced
Gastric Adenocarcinoma**

JAMA Oncology | *Research* |
April 4, 2024

**Targeted Therapy and
Survival Outcomes in
Patients With Metastatic
Colorectal Cancer**

JAMA Network Open |
Research | *January 19, 2023*

**Maintenance Therapy With
Cetuximab After FOLFIRI
Plus Cetuximab for RAS
Wild-Type mCRC**

JAMA Network Open |
Research | *September 18, 2023*